HCPS

Tangent90 announces strategic collaboration with NEJM Group

Retrieved on: 
Thursday, September 8, 2022
Partnership, HCP, Research, CEO, Technology, HCPS, Solution, The New England Journal of Medicine, Publishing, NEJM, Physician, Learning, Map, Publication, Communication, Originality, Industry, Management

LONDON, United Kingdom, Sep. 8, 2022 /PRNewswire-PRWeb/ -- Tangent90 Ltd, a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).

Key Points: 
  • LONDON, United Kingdom, Sep. 8, 2022 /PRNewswire-PRWeb/ -- Tangent90 Ltd , a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).
  • By working with Tangent90 to make these formats available to its clients via Trustrack, NEJM is expanding opportunities to engage physicians with its high-quality content.
  • Additionally, Tangent90 collaborated with NEJM to extend the Tangent90 Resource Centre platform to include NEJM Group content, tagged in a manner that will expose all appropriate content, beyond the traditional Original Research article.
  • "Our collaboration with NEJM Group will serve up more relevant scientific content in HCP communications, enabling pharma to better serve the HCP community, which ultimately results in better patient outcomes", he concluded.

Tangent90 announces strategic collaboration with NEJM Group

Retrieved on: 
Thursday, September 8, 2022
Partnership, HCP, Research, CEO, Technology, Massachusetts Medical Society, HCPS, Solution, The New England Journal of Medicine, Publishing, NEJM, Physician, Learning, Map, Medicine, Publication, Compliance, Communication, Originality, Knowledge, Industry, Efficiency, Management

LONDON, Sept. 8, 2022 /PRNewswire/ -- Tangent90 Ltd, a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).

Key Points: 
  • LONDON, Sept. 8, 2022 /PRNewswire/ -- Tangent90 Ltd , a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).
  • By working with Tangent90 to make these formats available to its clients via Trustrack, NEJM is expanding opportunities to engage physicians with its high-quality content.
  • Additionally, Tangent90 collaborated with NEJM to extend the Tangent90 Resource Centre platform to include NEJM Group content, tagged in a manner that will expose all appropriate content, beyond the traditional Original Research article.
  • NEJM Group products include the New England Journal of Medicine, NEJM Evidence, NEJM Journal Watch, NEJM Knowledge+, and NEJM Catalyst, NEJM Resident 360, NEJM Yi Xue Qian Yan and NEJM Career Center.

Tangent90 announces strategic collaboration with NEJM Group

Retrieved on: 
Thursday, September 8, 2022
Partnership, HCP, Research, CEO, Technology, Massachusetts Medical Society, HCPS, Solution, The New England Journal of Medicine, Publishing, NEJM, Physician, Learning, Map, Medicine, Publication, Compliance, Communication, Originality, Knowledge, Industry, Efficiency, Management

LONDON, Sept. 8, 2022 /PRNewswire/ -- Tangent90 Ltd, a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).

Key Points: 
  • LONDON, Sept. 8, 2022 /PRNewswire/ -- Tangent90 Ltd , a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).
  • By working with Tangent90 to make these formats available to its clients via Trustrack, NEJM is expanding opportunities to engage physicians with its high-quality content.
  • Additionally, Tangent90 collaborated with NEJM to extend the Tangent90 Resource Centre platform to include NEJM Group content, tagged in a manner that will expose all appropriate content, beyond the traditional Original Research article.
  • NEJM Group products include the New England Journal of Medicine, NEJM Evidence, NEJM Journal Watch, NEJM Knowledge+, and NEJM Catalyst, NEJM Resident 360, NEJM Yi Xue Qian Yan and NEJM Career Center.

​​​​​​​Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds

Retrieved on: 
Thursday, September 8, 2022
MBS, Technology, Health policy, HCPS, British Lung Foundation, Research, UNITED KINGDOM, Master of Science, Forecasting, Initiative, Royal Commission on the Future of Health Care in Canada, Solution, Disease, Paap, The Economist Group, GSK, Benchmarking, Hope, Risk, Policy, Leadership, Physician, Asthma, Time-invariant system, Chronic Respiratory Disease, Quality of life, Education, Creativity, EIU, Human, Medicine, Prevalence, Communication, Adult, Public policy, British, Degenerative disease, Gaps, Climate change, MPH, Asthma UK, Patient, GP, Pharmaceutical industry, Doctor of Philosophy, COVID-19

Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds

Key Points: 
  • Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds
    Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds
    A new study and survey by Economist Impact, with the support of GSK, shows the continuing work that needs to be done to improve quality of life for people living with asthma.
  • Poorly controlled asthma has a much higher economic burden than well managed asthma.
  • Economist Impact carried out a survey of asthma patients spanning 13 countries , looking at how they perceived their current treatment, as well as what hope they had for future care.
  • This survey highlights some of the needs and gaps along a patients asthma journey that still exist, and warrant continued efforts to improve asthma care.

Less than 50% of Asthma Patients Feel Their Condition Is Well Managed, Economist Impact Study Finds

Retrieved on: 
Tuesday, September 6, 2022
MBS, Technology, Health policy, HCPS, British Lung Foundation, Research, Master of Science, Forecasting, Initiative, Royal Commission on the Future of Health Care in Canada, Solution, Disease, Gerrit Paape, The Economist Group, GSK, Benchmarking, Hope, Risk, Policy, Leadership, Physician, Asthma, Time-invariant system, Chronic Respiratory Disease, Education, Quality of life, Creativity, EIU, Human, Medicine, Prevalence, Communication, Adult, Public policy, British, Degenerative disease, Gaps, Climate change, MPH, Asthma UK, Patient, GP, Pharmaceutical industry, Doctor of Philosophy, COVID-19

A new study and survey by Economist Impact, with the support of GSK, shows the continuing work that needs to be done to improve quality of life for people living with asthma.

Key Points: 
  • Compare that to those with controlled asthma, for whom these rates are similar to that of healthy people.
  • Economist Impact carried out a survey of asthma patients spanning 13 countries , looking at how they perceived their current treatment, as well as what hope they had for future care.
  • This survey highlights some of the needs and gaps along a patient's asthma journey that still exist, and warrant continued efforts to improve asthma care.
  • The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events and SignalNoise.

Medical Gloves Market Global Outlook 2022: Growing Demand for Powder-free or Non-powdered Medical Gloves Fueling Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Medical Supplies, Health, Allergy, University, COVID-19, Eyeish, HCPS, Ventilator-associated pneumonia, Research, Catheter-associated urinary tract infection, Oil, Virus, Incidence, Medicine, Latex, HAI, Infection, Hospital, VAP, Hospital-acquired infection, Methicillin-resistant Staphylococcus aureus, FDA, Automation, Personal protective equipment, Risk, PPE, Acid, Growth, Patient, Medical device, Natural rubber

Thus, the global medical gloves market is expected to grow as healthcare facilities, such as hospitals, diagnostics labs, clinics, and others, support the growth.

Key Points: 
  • Thus, the global medical gloves market is expected to grow as healthcare facilities, such as hospitals, diagnostics labs, clinics, and others, support the growth.
  • Due to this, the global gloves market is expected to boost as people are shifting to adopt non-powdered or powder-free gloves, synthetic gloves, or low-protein latex gloves.
  • It has further decreased medical glove costs and helped the global medical gloves market to grow significantly.
  • Hence, gloves have been mandated in the healthcare center to prevent spreading infections acting as a significant growth factor in the medical gloves market.

RxDefine launches new telehealth product for life sciences brands

Retrieved on: 
Thursday, September 1, 2022
Education, Multimedia, CEO, HCPS, Friction, Marketing, Pharmaceutical industry, Online shopping

MIAMI, Sept. 1, 2022 /PRNewswire/ -- RxDefine, a leading engagement platform dedicated to educating and empowering healthcare consumers and HCPs, today announced the launch of  RxTelehealth, its telehealth solution for life sciences brands. RxDefine's mission is to ethically empower people to navigate their own health decisions, and the launch of RxTelehealth is a critical step toward living this mission. For more information about telehealth for life sciences brands, read RxDefine's two-part series, 5 questions to ask about whether telehealth is right for your life sciences brand, and 5 things to look for when choosing a telehealth provider.

Key Points: 
  • MIAMI, Sept. 1, 2022 /PRNewswire/ -- RxDefine, a leading engagement platform dedicated to educating and empowering healthcare consumers and HCPs, today announced the launch of RxTelehealth, its telehealth solution for life sciences brands.
  • For more information about telehealth for life sciences brands, read RxDefine's two-part series, 5 questions to ask about whether telehealth is right for your life sciences brand , and 5 things to look for when choosing a telehealth provider .
  • "RxDefine is about making healthcare easier - for consumers, for health care providers, and for everyone else on the journey," said Dr. Chase Feiger, CEO of RxDefine.
  • "In launching RxTelehealth, our goal is to set the standard for what telehealth solutions for life sciences brands should be," said Gurjeev Singh, director of product management at RxDefine.

Partnership with ScienceMedia and MAPS Organization Builds New Avenues for Affordable Medical Affairs eLearning

Retrieved on: 
Thursday, September 1, 2022
Partnership, HCPS, SAN, Medical Affairs Bureau, SMI, Disease, Solution, MAPS, LinkedIn, Blog, Cros, Biotechnology, Turner, News, Clinical trial, Patient, Pharmaceutical industry, Medical imaging, Medical device

That's why MAPS is proud to partner with ScienceMedia to provide access for our members to the SMi Source library.

Key Points: 
  • That's why MAPS is proud to partner with ScienceMedia to provide access for our members to the SMi Source library.
  • We're thrilled to be filling a gap in affordable and authoritative eLearning resources for MAPS members."
  • MAPSis the premier non-profit global Medical Affairs organization FOR Medical Aairs professionals BY Medical Affairs professionals across all dierent levels of experience and specialties to engage, empower and educate.
  • Together with more than 9,000 Medical Affairs members from over 280 companies globally, MAPSis transforming the Medical Affairs profession to increase its value to patients, HCPs and other decision-makers.

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

Retrieved on: 
Thursday, September 1, 2022
Biotechnology, General Health, Pharmaceutical, Health, Partnership, COVID-19, Patient, CEO, HCP, OTC, Security (finance), HCPS, Securities Act of 1933, Research, NASDAQ, NR, Ageing, CERP, Nicotinamide mononucleotide, Brazilians, Sale, NMN, An Act to exempt a particular class of securities from the Securities and Exchange Act, ChromaDex, Policy, Risk, Food, ANVISA, Royal commission, Therapeutic Goods Administration, FSANZ, SEC, Health Canada, Natural health product, TGA, Vitamin B3, NAD, Â, Company, Compliance, History, Tru, Founder, Annual report, European Commission, Acquisition, Industry, Growth, Marketing, Food Standards Australia New Zealand, Online shopping

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand.
  • The cross-border distribution strategy allows for Tru Niagen 300mg 30 count bottles, Tru Niagen 300mg 90 count bottles and Tru Niagen 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier.
  • We are pleased to work with MyPharma2Go to introduce the healthy aging benefits of Tru Niagen to Brazil, said Rob Fried, CEO of ChromaDex.
  • Tru Niagen, Tru Niagen PRO and Tru Niagen Stickpacks are now available for sale in the Brazilian market on several cross-border marketplaces including www.saudecelular.com.br , www.mypharma2go.com , www.mundihealth.com and through HCP in-person sales.

ClinOne Supports 100+ Active Clinical Trials with 100% On-Time Delivery as Company Welcomes New CEO, Executives, and Partners in First Half 2022

Retrieved on: 
Wednesday, August 31, 2022
COO, VP, HCP, Technology, Caregiver, HCPS, Medicine, Consent management, Awareness, Televisit, Solution, HR, LinkedIn, API, Health, Cros, Compliance, Clinical trial, DCT, Marketing, Growth, Industry, CNS, Patient, Pharmaceutical industry, Oncology

BOSTON, Aug. 31, 2022 /PRNewswire-PRWeb/ -- ClinOne, the leading provider of Adaptive Experiences for clinical trial participants, surpassed a significant milestone in its growth as one of the industry's most watched companies by supporting more than 100 active trials in the first half of 2022 while achieving 100% on-time delivery and welcoming its new CEO, executives, and partners.

Key Points: 
  • ClinOne provides Adaptive Experiences to all participants in clinical trials to improve retention, compliance, and conduct efficiency.
  • The company's true single platform features proven solutions for Consent Management, HCP Trial Awareness, Patient Ride, Medication Adherence, TeleVisits, and more.
  • "We are on a mission to deliver Adaptive Experience solutions which truly support the clinical trial journey.
  • I've been on that mission my entire career and am so optimistic and excited about the possibilities here at ClinOne."